MedTrace Logo

Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV

NCT03129113 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-11-04

No results posted yet for this study

Summary

This is a multicentre, phase IV, randomised, open-label, trial exploring adjunctive maraviroc and/or metformin for liver steatosis over 48 weeks.

Sponsored by University College London Coordinated by MRC Clinical Trials Unit at UCL

Conditions

Interventions

DRUG

Maraviroc

1:1:1:1 randomisation to one of four arms for 48 weeks

DRUG

Metformin

1:1:1:1 randomisation to one of four arms for 48 weeks

Sponsors & Collaborators

  • Medical Research Council

    collaborator OTHER_GOV

  • ViiV Healthcare

    collaborator INDUSTRY

  • Royal Free Hospital NHS Foundation Trust

    collaborator OTHER

  • University College, London

    lead OTHER

Principal Investigators

  • Sarah Pett · UCL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2020-11-05
Completion
2020-11-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03129113 on ClinicalTrials.gov